Bio-Techne Announces Submission Of FDA Drug Master File For ExCellerate GMP iPSC Expansion Medium Supporting Stem Cell Therapy
Portfolio Pulse from Benzinga Newsdesk
Bio-Techne has submitted a Drug Master File to the FDA for its ExCellerate GMP iPSC Expansion Medium, which is designed to support stem cell therapy. This submission is a significant step for Bio-Techne as it aims to facilitate the development and commercialization of stem cell therapies, potentially accelerating the availability of these treatments to patients.
December 20, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Techne's submission of a Drug Master File for its ExCellerate GMP iPSC Expansion Medium to the FDA could positively impact the company's position in the stem cell therapy market and may lead to increased interest from investors in the short term.
The submission of the Drug Master File by Bio-Techne is directly related to the company's efforts to support stem cell therapy, which is a growing field in the biotechnology sector. This regulatory milestone can be seen as a positive development for the company, likely to be viewed favorably by investors. It demonstrates Bio-Techne's commitment to expanding its product offerings and could potentially lead to future revenue growth as the medium is adopted for use in stem cell therapies.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100